A new shingles vaccine has been approved in the US - ForumDaily
The article has been automatically translated into English by Google Translate from Russian and has not been edited.
Переклад цього матеріалу українською мовою з російської було автоматично здійснено сервісом Google Translate, без подальшого редагування тексту.
Bu məqalə Google Translate servisi vasitəsi ilə avtomatik olaraq rus dilindən azərbaycan dilinə tərcümə olunmuşdur. Bundan sonra mətn redaktə edilməmişdir.

A new shingles vaccine has been approved in the US

Фото: Depositphotos

A federal commission of experts on Wednesday recommended a new and more effective shingles vaccine to protect those who are 50 and older, writes The Washington Post.

The Advisory Committee also stated that the new vaccine Shingrix would be preferable to the existing vaccine Zostavaxbecause it provides much more protection.

On Friday, October 20, the Food and Drug Administration approved a new vaccine produced by GlaxoSmithKline PLC.

Shingrix is the first new vaccine f, or shingles vaccine (which is caused by the herpes virus) in a decade. For the first time, the Advisory Committee recommends that adults between the ages of 50 and 59 be vaccinated. This group has about 42 millions of Americans.

In addition, those who have previously been vaccinated ZostavaxIt is recommended to repeat vaccination with a new drug. This group includes approximately 20 million people.

“This is a major step forward for people who want to be protected from the disease and its complications,” said Kathleen Dooling, a medical officer at the Centers for Disease Control and Prevention.

The new vaccine has the potential to prevent tens of thousands of cases of shingles and thousands of cases of its most common complication, debilitating pain, she said.

The most common side effect is a reaction at the injection site, including redness or swelling, as well as muscle pain, fever and headache. Side effects can last up to three days.

Members of the committee had a fierce debate about recommending a new vaccine to replace the existing one. But they agreed that clinical trial data show the superior efficacy of the new vaccine. However, those who opposed the preferential recommendation expressed concern about the lack of data on its safety and effectiveness in real conditions. The vaccine requires two doses compared to the existing vaccine (1 dose).

Currently, analysts predict that annual sales Shingrix will reach 1,37 billion dollars in 2023 year in light of the positive recommendations of the United States.

Read also on ForumDaily:

What vaccinations does the US Citizenship and Immigration Service require?

How two friends created useful toys and contributed to the fight against autism

What I learned about medicine in the United States when I got insurance

What you need to know before you go on a cruise

Miscellanea In the U.S. virus медицина disease vaccine vaccinations
Subscribe to ForumDaily on Google News

Do you want more important and interesting news about life in the USA and immigration to America? — support us donate! Also subscribe to our page Facebook. Select the “Priority in display” option and read us first. Also, don't forget to subscribe to our РєР ° РЅР ° Р »РІ Telegram  and Instagram- there is a lot of interesting things there. And join thousands of readers ForumDaily New York — there you will find a lot of interesting and positive information about life in the metropolis. 



 
1072 requests in 1,188 seconds.